1. Academic Validation
  2. ETS Proto-Oncogene 1 Suppresses MicroRNA-128 Transcription to Promote Osteogenic Differentiation Through the HOXA13/β-Catenin Axis

ETS Proto-Oncogene 1 Suppresses MicroRNA-128 Transcription to Promote Osteogenic Differentiation Through the HOXA13/β-Catenin Axis

  • Front Physiol. 2021 Mar 3;12:626248. doi: 10.3389/fphys.2021.626248.
Renyao Li 1 Ying Dong 1 Feipeng Li 2
Affiliations

Affiliations

  • 1 School of Biological Science and Medical Engineering, Beihang University, Beijing, China.
  • 2 Naton Biotech (Beijing) Co., Ltd., Beijing, China.
Abstract

ETS proto-oncogene 1 (ETS1) has been implicated in osteoporosis (OP), but the exact molecular mechanisms are complex. This work focuses on the impact of ETS1 on the osteogenic differentiation and the molecules involved. A mouse pre-osteoblast cell line MC3T3-E1 was used for in vitro experiments. ETS1 was upregulated during the process of osteogenic differentiation of MC3T3-E1 cells. Overexpression of ETS1 promoted expression of osteogenic markers, alkaline phosphate concentration, and calcareous accumulation in cells. ETS1 was found to specifically bind to miR-128 promoter to suppress its transcription, while miR-128 could target homeobox A13 (HOXA13). Therefore, ETS1 suppressed miR-128 transcription to upregulate HOXA13 expression. Overexpression of HOXA13 promoted the osteogenic differentiation ability of cells and increased the protein level of β-catenin. Either overexpression of miR-128 or downregulation of β-catenin by CWP232228, a β-catenin-specific antagonist, blocked the promoting roles of ETS1 in cells. To conclude, this study provided evidence that ETS1 suppresses miR-128 transcription to activate the following HOXA13/β-catenin axis, therefore promoting osteogenic differentiation ability of MC3T3-E1 cells. This finding may offer novel ideas for OP treatment.

Keywords

E26 transformation-specific-1; HOXA13; microRNA-128; osteogenic differentiation; osteoporosis; β-catenin.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18959
    98.41%, Wnt/β-catenin Inhibitor